Indaptus Therapeutics is trading 10.59% up now at $3.55 as biotechnology shares rebound alongside a stronger broader market.
- The biotech sector is benefiting from improving pharmaceutical and biotech demand, healthier funding conditions, and renewed M&A optimism.
- No fresh company-specific announcement was identified for September 17, 2026.
- The recent approximately $24 million private placement remains relevant background; the move appears primarily sector-driven.